Aromatase inhibitors-Gene discovery

Journal of Steroid Biochemistry and Molecular Biology

Volumn 106, Issue 1-5, 2007, Pages 130-142

  Miller, William R ^a   Larionov, Alexey ^a   Renshaw, Lorna ^a   Anderson, Thomas J ^a   White, Sharon ^a   Hampton, Garret ^b   Walker, John R ^b   Ho, Steven ^b   Krause, Andreas ^c   Evans, Dean B ^c   Dixon, J Michael ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aromatase inhibitors gene discovery

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; LETROZOLE; RNA;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GENE THERAPY; CELL CYCLE PROGRESSION; CONTROLLED STUDY; ENZYME INHIBITION; ESTROGEN RELEASE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MITOSIS; RNA ANALYSIS;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CLUSTER ANALYSIS; DATABASES, NUCLEIC ACID; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POSTMENOPAUSE;

EID: 34548433015     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.05.013     Document Type: Article

References (46)

1. Carpenter R., and Miller W.R. Role of aromatase inhibitors in breast cancer. Br. J. Cancer 93 (2005) S1-S5
2. Dixon J.M., Anderson T.J., and Miller W.R. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur. J. Cancer 38 (2002) 2214-2221
3. Buzdar A.U. Data from the arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clin. Cancer Res. 10 (2004) 355S-361S
4. Coombes R.C., Hall E., Gibson L.J., et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
5. Eiermann W., Paepke S., Appfelstaedt J., and Letrozole Neoadjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole. A randomised double-blind multicentre study. Ann. Oncol. 12 (2001) 1527-1532
6. Goss P.E., Ingle J.N., and Martino S. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349 (2003) 1793-1802
7. Smith I.E., and Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348 (2003) 2431-2442
8. Winer E.P., Hudis C., and Burstein H.J. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J. Clin. Oncol. 21 (2003) 2597-2599
9. Miller W.R. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin. Oncol. 30 (2003) 3-11
10. Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 20 (2002) 751-757
11. Miller W.R., and Dixon J.M. Local endocrine effects of aromatase inhibitors within the breast. J. Steroid Biochem. Mol. Biol. 79 (2001) 93-102
12. Miller W.R. Biological rationale for endocrine therapy in breast cancer. Best Practice Res. Clin. Endocr. Metab. 18 (2004) 1-32
13. Iqbal S., Anderson T.J., Marson L.P., Prescott R.J., Dixon J.M., and Miller W.R. MIB-1 assessments in breast cancers. Breast 11 (2002) 252-256
14. Scherer A., Krause A., Walker J.R., Sutton S.E., Serón D., Raulf F., and Cooke M.P. Optimized protocol for linear RNA amplification and application to gene expression profiling of human renal biopsies. BioTechniques 34 (2003) 546-556
15. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs B., and Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31 (2003) e15
16. Irizarry R.A., Hobbs B., and Collin F. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2003) 249-264
17. R Development Core Team. R: a Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, 2006.
18. Gentleman R.C., Carey V.J., and Bates D.M. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5 (2004) R80
19. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5116-5121
20. H. Schwender, A. Krause, K. Ickstadt, Identifying interesting genes with siggenes, R-News, in press.
21. de Hoon M.J., Imoto S., Nolan J., and Miyano S. Open source clustering software. Bioinformatics 20 (2004) 1453-1454
22. Saldanha A.J. Java Treeview-extensible visualization of microarray data. Bioinformatics 20 (2004) 3246-3248
23. Miller W.R. Aromatase inhibitors. Endocr. Related Cancer 3 (1996) 65-79
24. D.W. Combs, Recent developments in aromatase inhibitors, Expert Opin. Ther. Patients 5 (1995) 529-534.
25. Lonning P.E. Pharmacology and clinical experience with exemestane. Expert Opin. Investig. Drugs 91 (2000) 1897-1905
26. Dowsett M., Jones A., Johnston S.R., Jacobs S., Trunet P., and Smith I.E. In vitro measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin. Cancer Res. 1 (1995) 1511-1515
27. Itoh T., Karlsberg K., and Kijima I. Letrozole-, anastrozole- and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Mol. Cancer Res. 3 (2005) 203-218
28. Miller W.R., White S., Dixon J.M., Murray J., Renshaw L., and Anderson T.J. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br. J. Cancer 94 (2006) 1051-1056
29. Miller W.R., Dixon J.M., Macfarlane L., Cameron D., and Anderson T.J. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur. J. Cancer 39 (2004) 462-468
30. Frasor J., Danes J.M., Komm B., Chang K.C., Lyttle C.R., and Katzenellenbogen B.S. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 (2003) 4562-4574
31. Oh D.S., Troester M.A., and Usary J. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J. Clin. Oncol. 24 (2006) 1656-1664
32. Lin C.Y., Strom A., and Vega V.B. Discovery of estrogen receptor α target genes and response elements in breast tumor cells. Genome Biol. 5 (2004) R66
33. Frasor J., Stossi F., Danes J.M., Komm B., Lyttle C.R., and Katzenellenbogen B.S. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 64 (2004) 1522-1533
34. Gosh M.G., Thompson D.A., and Weigel R.J. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res. 60 (2000) 6367-6375
35. Martin L.A., Pancholi S., and Chan C.M. The anti-oestrogen ICI 182, 780, but not tamoxifen inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr. Related Cancer 12 (2005) 1017-1036
36. Surmacz E., and Bartucci M. Role of estrogen receptor alpha in modulating IGF-1 receptor signalling and function in breast cancer. J. Exp. Clin. Cancer Res. 23 (2004) 385-394
37. Brockdorff B.L., Heiberg I., and Lykkesfeldt A.E. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor I alpha. Endocr. Related Cancer 10 (2003) 579-590
38. Molloy C.A., May F.E., and Westley B.R. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J. Biol. Chem. 275 (2000) 12565-12571
39. Ellis M.J., Coop A., and Singh B. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19 (2001) 3808-3816
40. Dressman M.A., Walz T.M., and Lavedan C. Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies. Pharmacogenomics J. 1 (2001) 135-141
41. Aitken S.C., and Lippman M.E. Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res. 45 (1985) 1611-1620
42. Foster J.S., and Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol. 10 (1996) 488-498
43. Moggs J.G., Murphy T.C., and Lim F.L. Anti-proliferative effect of estrogen in breast cancer cells that re-express Erα is mediated by aberrant regulation of cell cycle genes. J. Mol. Endocr. 34 (2005) 535-551
44. Miller W.R. Aromatase inhibitors and breast cancer. Minerva Endocrinol. 31 (2006) 27-46
45. Ring A., and Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Related Cancer 11 (2004) 643-658
46. Ali S., and Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2 (2002) 101-112